Kommentar
The KRAS tour: Studying metabolic reprogramming in isogenic pancreatic cancer organoids
Cell Stem Cell · 2024
DOI: 10.1016/j.stem.2023.12.010 ↗Kurz gefasst
Kommentar in der Zeitschrift Cell Stem Cell, 2024. Verfasst von Shree Bose und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Chicago, Chicago, IL, USA. Hauptthemen laut MEDLINE: Metabolic Reprogramming, Pancreatic Neoplasms. Die Arbeit nennt 10 Literaturangaben. Gefördert von: NCI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Metabolic ReprogrammingPancreatic NeoplasmsHumansLipid MetabolismOrganoidsProto-Oncogene Proteins p21(ras)
Substanzen
KRAS protein, humanProto-Oncogene Proteins p21(ras)
Autor:innen und Institutionen
- Department of Internal Medicine, University of Chicago, Chicago, IL, USA.
- Terasaki Institute for Biomedical Innovation, Los Angeles, CA, USA. Electronic address: xiling.shen@terasaki.org.
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Bose, S., & Shen, X. (2024). The KRAS tour: Studying metabolic reprogramming in isogenic pancreatic cancer organoids. Cell Stem Cell. https://doi.org/10.1016/j.stem.2023.12.010
Vancouver
Bose S, Shen X. The KRAS tour: Studying metabolic reprogramming in isogenic pancreatic cancer organoids. Cell Stem Cell. 2024. doi:10.1016/j.stem.2023.12.010
BibTeX
@article{Bose2024,
author = {Bose, Shree and Shen, Xiling},
title = {The KRAS tour: Studying metabolic reprogramming in isogenic pancreatic cancer organoids},
journal = {Cell Stem Cell},
year = {2024},
doi = {10.1016/j.stem.2023.12.010}
}
EUVIMED